Machine learning redefines precision cancer therapy using smart radiopharmaceuticals
Posted:
JMIR Publications released a feature News and Perspectives story on technological advances in oncology. Authored by JMIR Correspondent Benedette Cuffari, "AI-Designed Radiopharmaceuticals: How Machine Learning Is Redefining Precision Cancer Therapy" reports on the integration of deep learning and generative AI in radiopharmaceutical medicine, its impact on accelerating drug design, and how personalized dosimetry can improve patient outcomes.
Alzheimer’s disease is the most common cause of dementia, responsible for up to 80% of dementia cases worldwide.
In a mouse model, KCL-286, a drug that has passed phase 1 trials for spinal injuries in people, repaired DNA breaks and…
Neko Health has raised US$700m to fund its first US expansion, new clinics and further development of its preventative health tech.
The Series C round follows a US$260m Series B in January 2025.
Founded by Spotify’s Daniel Ek and Hjalmar…
Attendees
Sponsors and Exhibitors
Contact us